Startup profile · funding coverage
Acclinate funding, valuation and investors
Digital health equity platform using NOWINCLUDED community engagement and AI to improve clinical trial diversity.
Keep track of Acclinate
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$7M · May 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$7M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Birmingham, AL
Investors in latest funding
Lead: Cencora Ventures
Other: Labcorp , Latimer Ventures
Overview
Acclinate helps life-sciences sponsors recruit and retain more representative clinical trial participants. Co-founded in 2020 by Del Smith and Tiffany Whitlow, the company combines its NOWINCLUDED community platform — culturally relevant health education and research opportunities for underrepresented populations — with AI/ML tools (including its e-DICT platform) that help sponsors plan and run more inclusive studies. Headquartered in Birmingham, AL, Acclinate closed a $7M Series A in May 2024 led by Cencora Ventures, with Labcorp and Latimer Ventures participating. Earlier investors include Birmingham-based 450 Ventures.
Why Acclinate is interesting
FDA and pharma pressure on trial diversity created a commercial market Acclinate attacks with a community product (NOWINCLUDED) plus AI recruitment tech — not another patient-finder agency. Birmingham HQ; Series A led by a drug-distribution giant’s venture arm.
Product & use cases
Acclinate sells sponsors access to engaged communities via NOWINCLUDED and AI-assisted tools that surface representative cohorts, reduce recruitment friction, and support more inclusive protocol planning.
- Pharma and biotech sponsors improving racial and ethnic representation in trials
- CROs and sites needing community-trusted outreach beyond traditional recruitment vendors
- Sponsors planning future studies with predictive diversity insights
Key facts
- Series A (May 2024): $7M led by Cencora Ventures; Labcorp and Latimer Ventures participated
- NOWINCLUDED community platform plus e-DICT AI for clinical trial diversity
- HQ Birmingham, AL; founded 2020 by Del Smith and Tiffany Whitlow
- Seed backing includes Birmingham corporate VC 450 Ventures
Funding history (newest first)
Series A
2024-05 $7M- Cencora Ventures (lead)
- Labcorp (participant)
- Latimer Ventures (participant)
Investors in our directory
Funds linked from Acclinate's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Pairs always-on community trust (NOWINCLUDED) with AI recruitment analytics — harder for pure staffing/recruitment shops to copy than a database alone.
-
Traditional patient recruitment agencies incumbent
Often transactional enrollment; less community ownership.
-
Trial matching marketplaces adjacent
Match patients to trials; may lack deep community engagement layer.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Acclinate's financing or category context.
FAQs about Acclinate
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.